Luminar Technologies Bolsa (NASDAQ: LAZR)

Últimas noticias sobre Luminar Technologies (NASDAQ:LAZR) Bolsa

Luminar Technologies

Luminar Technologies Inc is an automotive technology company ushering in a new era of vehicle safety and autonomy. It operates its business through the following segments: Autonomy Solutions and Advanced Technologies and Services. The majority of its revenue is generated from the Autonomy Solutions segment, which engages in the design, manufacturing, and sale of LiDAR sensors, catering mainly to the OEMs in the automobile, commercial vehicle, robo-taxi, and adjacent industries. The Advanced Technologies and Services segment provides semiconductors and related components, as well as design, test, and consulting services to the Autonomy Solutions segment and various third-party customers. Geographically, the company derives its key revenue from North America.

Xpeng, Hesai Group, Kohl's, Groupon, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Equities

News

Markets

BABA

INTC

LAZR

RDDT

TSLA

El S&amp;P 500 sube, pero cierra su cuarta semana en rojo. Descubre qué acciones captaron la atención de los traders el lunes.

Tesla, Luminar, Reddit, Intel, Alibaba: 5 acciones que están en el radar de los inversores

Luminar Technologies, Inc. - Class A Common Stock

Luminar Technologies Inc

Stanford-educated roboticist Samir Menon never set out to replace human workers with machines. He wants to &#8216;supercharge&#8217; them, and now his billion-dollar startup, Dexterity, is betting that vision could shape the future of global labor.
Founded in 2017, Dexterity builds what it calls "superhumanoids," industrial <a href="https://www.benzinga.com/news/25/05/45185633/ups-explores-humanoid-robots-as-figure-ai-secures-675m-from-jeff-bezos-openai-and-intel-targeting-9b-revenue-by-2029">robots</a> designed to work in extreme conditions like high heat or altitude, where human labor often falls short. The company is currently valued at $1.65 billion and has entered unicorn territory with backing from major players like FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) and Kawasaki Heavy Industries,<a href="https://www.wsj.com/tech/ai/unicorn-startup-that-makes-superhuman-robots-plots-path-to-ipo-2a84abbe"> The Wall Street Journal</a> reports.
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
Rather than designing robots to mimic human shape and behavior, Menon's team focuses on utility, building machines that can lift heavier, last longer, and handle riskier tasks than any person safely could. "You can try to do <a href="https://www.benzinga.com/news/topics/25/06/45961532/nvidia-and-samsung-back-4-5b-robotics-startup-skild-ai-with-35m-as-softbank-and-jeff-bezos-drive-push-into-consumer-robots">robotics</a> in a way that you're replacing people, or you can try to do it in a way that you're supercharging people," Menon told The Journal at the ATxSummit in May in Singapore.
<h2 class="wp-block-heading">Inspired by "Transformers," Built for Supermarkets</h2>
Dexterity's flagship robot is called the Mech, a mobile, two-armed machine inspired in part by "Transformers" and "Pacific Rim". According to the Journal, Mech is designed to perform physically demanding work that's too dangerous or repetitive for human workers, such as lifting heavy parcels or operating in logistics hubs.
With partners like FedEx and Sumitomo Corp. already signed on, Menon sees supermarkets and airports as likely next steps, noting to the Journal that these are examples of where robots could become commonplace.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
Market forecasts support Menon's optimism. According to<a href="https://www.morganstanley.com/insights/articles/humanoid-robot-market-5-trillion-by-2050"> Morgan Stanley</a>, the humanoid robotics industry could be worth $5 trillion by 2050, with more than 1 billion robots deployed across commercial and industrial environments.
"Adoption should be relatively slow until the mid-2030s, accelerating in the late 2030s and 2040s," Adam Jonas, Morgan Stanley's head of global autos and shared mobility research, said in a note. "The forecast for household usage is much more conservative, with only 80 million humanoids in homes by 2050. We are not going to see a robot in every home overnight."
<h2 class="wp-block-heading">IPO in Sight as Labor Shortages Push Demand for Industrial Robots</h2>
Dexterity is in active fundraising mode and plans to go public in the U.S. once it achieves stable revenue and scalability, according to Menon. The Journal says he's prioritizing growth for now, with profitability still a few years away.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<a href="https://www.bain.com/contentassets/d620202718c146359acb05c02d9060db/bain-report_the-working-future.pdf">Bain &amp; Co</a> estimates that by 2030, the global economy could face a shortage of nearly 8 million manufacturing workers, a gap that robots like Dexterity's Mech could help fill. In countries like the U.S., Japan, and much of Europe, shrinking workforces and aging populations are accelerating the demand for non-disruptive automation solutions.
For Menon, the key lies in designing machines that solve labor problems without sparking panic. "A lot of people don't really want to do extremely low-paying, very stressful tasks," he told the Journal, emphasizing that many of these roles can be augmented rather than erased.
As Dexterity scales, Menon says it's developing industrial robots aimed at amplifying human labor in high-stress or physically extreme environments, The Journal reports.
Read Next: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
Image: Shutterstock

Stanford PhD Building 'Superhumanoids' Says Robots Won't Replace Us — They'll 'Supercharge People' As $1.65B Startup Eyes IPO

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) has outperformed the market over the past 10 years by 17.86% on an annualized basis producing an average annual return of 29.33%. Currently, ServiceNow has a market capitalization of $209.99 billion. 
Buying $100 In NOW: If an investor had bought $100 of NOW stock 10 years ago, it would be worth $1,323.38 today based on a price of $1013.70 for NOW at the time of writing.
<h3>ServiceNow's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752104712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In ServiceNow 10 Years Ago Would Be Worth This Much Today

Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) has outperformed the market over the past 5 years by 7.53% on an annualized basis producing an average annual return of 21.9%. Currently, Reinsurance Gr has a market capitalization of $12.91 billion. 
Buying $100 In RGA: If an investor had bought $100 of RGA stock 5 years ago, it would be worth $275.20 today based on a price of $195.28 for RGA at the time of writing.
<h3>Reinsurance Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752103813_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Reinsurance Gr Stock In The Last 5 Years

The risk of unauthorized data collection and privacy breaches has surged as generative AI and large language models (LLMs) become embedded in everyday tools and services. Here's a look at some of the least invasive AI platforms, as well as the most <a href="https://www.benzinga.com/markets/tech/25/07/46187301/elon-musks-xai-secures-10-billion-in-debt-and-equity-amid-soaring-burn-rate-as-ai-arms-race-intensifies">aggressive data collectors.&nbsp;</a>
What To Know: According to a recent<a href="https://blog.incogni.com/ai-llm-privacy-ranking-2025/"> report </a>from Incogni, Mistral AI's Le Chat emerged as the least invasive AI platform in terms of data privacy, limiting data collection and performing well across most criteria.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/politics/25/07/46308025/get-ready-for-800-hours-of-blackouts-trumps-doe-warns?utm_source=articleShare">Get Ready For 800 Hours Of Blackouts, Trump&#8217;s DOE Warns</a>&nbsp;
ChatGPT (OpenAI) ranked second, followed by Grok (xAI) with both generative AI platforms offering relatively clear privacy policies and the ability for users to opt out of having their data used in model training.
At the other end of the spectrum, Meta Platforms, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Meta AI, Alphabet, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Gemini and Copilot from Microsoft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) were found to be the most aggressive in data collection and least transparent about their practices. 
DeepSeek also performed poorly, particularly regarding opt-out options and policy clarity.
Anthropic and Meta also disclose sharing with <a href="https://www.benzinga.com/markets/tech/25/07/46197734/metas-superintelligence-lab-wants-to-outthink-the-world-and-scale-ai-dna-is-all-over-it">research collaborators</a>, which could raise concerns about data control once prompts leave the platform. 
Mobile app data collection practices were also scrutinized. Le Chat, Pi AI and ChatGPT had the lowest privacy risk on mobile. Meta AI's mobile app was the most aggressive and collected usernames, emails and phone numbers.&nbsp;
Gemini and Meta AI collect exact user locations, and Pi AI, Gemini, and DeepSeek collect phone numbers. Grok shares photos and app interaction data, while Anthropic's Claude shares app usage and email addresses.
User Beware: Overall, privacy risks vary widely between generative AI platforms.&nbsp;
The best performers offered clear <a href="https://www.benzinga.com/markets/tech/25/07/46301582/metas-ai-empire-grows-fueled-by-openai-deepmind-apple-defectors">privacy policies</a>, opt-out controls and minimal data collection, while the worst offenders lacked transparency and shared user data broadly without clear justification.
Users should research generative AI platform privacy policies and understand and use privacy controls in order to limit security risks and maintain control of personal data.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46326465/unitedhealth-slammed-with-another-lawsuit-over-119-billion-stock-plunge?utm_source=articleShare">UnitedHealth Slammed With Another Lawsuit Over $119 Billion Stock Plunge</a></li>
</ul>
Image: Shutterstock

Large Cap

Tech

GOOG

GOOGL

MSFT

Meta, Copilot Flunk AI Privacy 101 — Big Tech Is Playing Chicken With Your Privacy

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) stock traded above its 50-day moving average and close to its 52-week high of $747.90 on Wednesday.
The stock has surged 26% year-to-date, topping the Nasdaq 100 index&#8217;s ~9% and the S&amp;P 500 index&#8217;s over 6%.
The Facebook and Instagram parent gained over 25% in the last three months, compared to the Nasdaq 100&#8217;s over 19% and the S&amp;P 500&#8217;s over 14%.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/46117348/meta-secures-more-clean-energy-for-power-hungry-ai-and-data-center-growth" rel="noreferrer noopener">Meta Secures More Clean Energy For Power Hungry AI And Data Center Growth</a>
<h2 class="wp-block-heading">What Has Driven Meta&#8217;s Rally?</h2>
Meta aims to unlock value by strategically investing in AI and its core products. The company focuses on boosting user engagement, upgrading its advertising tools, and launching new AI-driven features.
Meta <a target="_blank" href="https://www.benzinga.com/tech/25/01/43072303/mark-zuckerberg-stands-to-gain-from-tiktoks-us-ban-analysis-shows-meta-could-reap-billions-in-ad-revenue" rel="noreferrer noopener">also stands to</a> gain billions of dollars from a potential TikTok ban as it erases a direct competitor to the social media platform.
Meta is expanding <a target="_blank" href="https://www.benzinga.com/markets/equities/25/02/44031320/mark-zuckerbergs-meta-wants-to-do-an-ai-app-but-sam-altman-wants-to-pull-a-reverse-uno-card-maybe-well-do-a-social-app" rel="noreferrer noopener">its AI efforts</a> by making Meta AI available across Facebook, Instagram, and WhatsApp, where it already reaches around 700 million users.
The company also plans to test a paid subscription model similar to ChatGPT&#8217;s premium tier. CEO Mark Zuckerberg said Meta is focused on scaling a smart, personalized AI assistant to over 1 billion people this year, positioning Meta AI as a market leader.
To support these efforts, Meta is ramping up capital spending on AI infrastructure, including data centers, and expanding its AI workforce.
<h2 class="wp-block-heading">Meta&#8217;s Latest Quarterly Results</h2>
On April 30, Meta reported <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/45117948/meta-q1-earnings-eps-beat-revenue-up-16-ai-approaches-1-billion-monthly-actives-capital-expenditures-forecast-raised" rel="noreferrer noopener">first-quarter revenue</a> of $42.31 billion, up 16% on a year-over-year basis, beating&nbsp;analyst estimates of $41.39 billion.&nbsp;
Family daily active people climbed 6% to 3.43 billion. Ad impressions jumped 5%, and the average price per ad increased by 10%.
Operating margins totaled 41%, up from 38% in the prior year&#8217;s quarter.&nbsp;
Meta expects second-quarter revenue of $42.5 billion-$45.5 billion versus&nbsp;estimates of $44.06 billion.
The company anticipates full-year capital expenditures of $64 billion to $72 billion (up from prior guidance of $60 to $65 billion), which reflects additional data center investments to support its artificial intelligence efforts and an increase in the expected cost of infrastructure hardware.
<h2 class="wp-block-heading">How Is Meta Accomplishing Its Ambitions?</h2>
On January 14, Meta announced <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/42986509/meta-platforms-announces-performance-based-job-cuts-whats-going-on" rel="noreferrer noopener">performance-based job cuts</a> that could impact about 5% of its 72,000 workers. The company cited its plans to raise the bar on performance management and move out low-performers faster.
Meta is actively recruiting <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46301582/metas-ai-empire-grows-fueled-by-openai-deepmind-apple-defectors" rel="noreferrer noopener">top AI talent</a> from rivals like OpenAI, Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google DeepMind, Anthropic, and Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to accelerate its artificial general intelligence (AGI) push through its Superintelligence Labs (MSL), launched in June 2025.
Under CEO Mark Zuckerberg&#8217;s leadership, Meta has consolidated its Llama models and FAIR research into MSL, aiming to build &#8220;personal superintelligence&#8221; for its platforms.
Meta has hired seven researchers from OpenAI to power this vision, including experts in large language models and reinforcement learning, machine learning veteran Jack Rae, and image generation specialist Huiwen Chang from Google DeepMind.
Apple&#8217;s former Foundation Models lead, Ruoming Pang—behind projects like Genmoji and Siri upgrades—joined MSL with a reported multimillion-dollar offer. Meta added Claude developer Anton Bakhtin and inference specialist Joel Pobar from Anthropic.
Led by Alexandr Wang and Nat Friedman and supported by a $14.3 billion investment in Scale AI, MSL is rapidly assembling a high-caliber AI team.
<h2 class="wp-block-heading">Meta&#8217;s Inorganic Growth Strategy</h2>
Meta is in talks to acquire <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/46141985/metas-play-for-voice-ai-could-shake-up-the-competition" rel="noreferrer noopener">voice-cloning AI startup</a> PlayAI along with some of its employees, according to Bloomberg sources.
While financial details remain undisclosed, the move reflects Meta&#8217;s push to develop a &#8220;superintelligence&#8221; lab and strengthen its position amid rising competition in the AI voice assistant market.
Meta is also <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45880561/meta-on-the-verge-of-a-15-billion-deal-with-scale-ai-report" rel="noreferrer noopener">reportedly planning a</a> $15 billion investment in data-labeling startup Scale AI for a 49% stake and aims to bring its co-founder, Alexandr Wang, along with key researchers, on board. This move aligns with Meta&#8217;s strategy to build a &#8220;superintelligence&#8221; lab.
<h2 class="wp-block-heading">What Does Wall Street Think About Meta</h2>
Forty-three analysts have set a <a target="_blank" href="https://www.benzinga.com/quote/META/analyst-ratings" rel="noreferrer noopener">forecast</a> of $734.93 for Meta. Tigress Financial issued the highest forecast, $935, on February 11, 2025, while Scotiabank gave the lowest, $525, on April 21, 2025.
Recent ratings from TD Cowen, Roth Capital, and Wells Fargo average $774.33, suggesting a potential 5.33% upside for the stock based on their projections.
Following its first-quarter results, Guggenheim analyst Michael Morris named Meta the best-positioned <a target="_blank" href="https://www.benzinga.com/25/05/45144725/meta-analysts-highlight" rel="noreferrer noopener">digital advertising company</a>. JPMorgan&#8217;s Doug Anmuth reaffirmed Meta as a &#8220;top pick,&#8221; citing growing momentum behind its AI models, Andromeda and GEM.
Several Wall Street analysts agreed that Meta is well equipped to perform in a weaker macroeconomic climate and praised its capital spending as a solid foundation for future growth.
However, Needham analyst Laura Martin raised concerns about Meta&#8217;s long-term value, pointing out that the company doesn&#8217;t control its distribution channels or content and faces intense competition from Apple, TikTok, and YouTube.
TD Cowen&#8217;s John Blackledge flagged risks including declining engagement among younger users, regulatory and legal challenges, increasing competition, and the high costs of Reality Labs.
On March 18, Wolfe Research highlighted Meta&#8217;s WhatsApp business messaging, unlocking a <a target="_blank" href="https://www.benzinga.com/markets/25/03/44374847/meta-could-rake-in-30-40-billion-in-revenue-from-whatsapp-business-messaging-predicts-analyst" rel="noreferrer noopener">total addressable market of $30–$40 billion</a> (TAM).
Analysts expect Meta&#8217;s integration of AI agents for small business customer service to boost WhatsApp revenue significantly.
With WhatsApp currently contributing just $1.5–$2 billion, Wolfe noted
On July 3, Needham&#8217;s Laura Martin flagged Meta&#8217;s soaring capex—expected to rise 84% to $68 billion in 2025—<a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/upgrades/25/07/46245952/metas-growth-sizzles-but-wait-for-a-pullback-before-buying-in" rel="noreferrer noopener">as a concern</a> for future returns.
She questioned Meta&#8217;s capital allocation amid heavy spending on GenAI, metaverse, Scale AI, and hardware ventures. Martin also cited regulatory risks and high investor expectations, cautioning that Meta may be overvalued at current levels.
Price Action: META stock closed up by 1.68% to $732.78 on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46252872/why-amazon-lags-its-peers-in-2025" target="_blank" rel="noreferrer noopener">Why Amazon Lags Its Peers In 2025</a></li>
</ul>
Photo via Shutterstock

AAPL

Meta Has Gained 26% In 2025, Can The Rally Continue?

Watts Water Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTS#NYSE">WTS</a>) has outperformed the market over the past 15 years by 3.12% on an annualized basis producing an average annual return of 15.41%. Currently, Watts Water Technologies has a market capitalization of $8.56 billion. 
Buying $1000 In WTS: If an investor had bought $1000 of WTS stock 15 years ago, it would be worth $8,476.05 today based on a price of $256.57 for WTS at the time of writing.
<h3>Watts Water Technologies's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752102015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Watts Water Technologies 15 Years Ago Would Be Worth Today

Billionaires Elon Musk and Mark Zuckerberg almost ended up <a href="https://www.benzinga.com/general/social-media/25/01/42833727/dana-white-wanted-elon-musk-mark-zuckerberg-in-cage-fight-now-hes-on-metas-board-of-directors">in a cage fight </a>over their competing social media platforms. Musk may not want to look at the latest metrics from X rival Threads, or he could be proposing a cage match again.
What Happened: Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) launched Threads in 2023 and was viewed as a potential X killer and a new social media platform to lure users from Musk's platform. Threads has grown to more than <a href="https://www.benzinga.com/general/social-media/25/05/45140138/mark-zuckerberg-celebrates-threads-milestone-x-competitor-next-major-social-app">350 million registered users</a> and according to new metrics, is nearing X in one category.
In June, Threads had 115.1 million daily active users on the mobile app, according to data from Similarweb shared by <a href="https://techcrunch.com/2025/07/07/threads-is-nearing-xs-daily-app-users-new-data-shows/">TechCrunch</a>. That total was up 127.8% year-over-year and also came closer to X than in past months.
X had 132 million daily active users on mobile in June, which was down 15.2% year-over-year.
Bluesky, another social media rival, trailed both with 4.1 million daily active users on mobile in June, but that figure was up an impressive 372.5% year-over-year.
For U.S. users, the data was also close. X had 33.1 million daily active users for mobile in June, while Threads had 15.3 million daily active users. Bluesky had around 1.1 million daily active users for U.S. mobile in June.
The data shows that Threads is seeing an increase in mobile usage while X is seeing declines. The lines of daily active users are getting closer together, at least for mobile. This comes as Meta said it passed the 350 million monthly active users milestone for Threads recently and is working on further monetizing this user base.
X, which is no longer public, had 600 million monthly active users in 2024, according to data from Musk.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul class="wp-block-list">
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: While Threads is closing the gap for mobile daily active users in the latest data, it still has a long way to go for web visits.
Similarweb data showed that X had 145.8 million daily web visits in June, compared to only 6.9 million daily web visits for Threads. Bluesky was even lower at 5.3 million daily web visits.
The data for the U.S. region was similar, with X having 33.1 million daily web visits in June, with Threads having 985,200 daily web visits and Bluesky having 2.4 million daily web visits.
This shows that X still ranks as one of the most visited social media platforms and gets significantly more web traffic than Threads. Threads was set up as a mobile app, with the web version launched later. 
Add it up, and X is still dominant over Threads, but it should be worried about mobile growth for Threads and usage decline on its platform.
While there is room for many social media platforms, users in the U.S. and around the world only have so much time to commit to each platform, and X and Threads both want to get as much usage and monetization opportunities as possible.
The battle between X and Threads comes with Musk and Zuckerberg are also the two richest people in the world at this time. Musk is the world's richest person, worth $349 billion according to <a href="https://www.bloomberg.com/billionaires/">Bloomberg</a>. Zuckerberg ranks second with $254 billion.
Similar to their mobile usage trajectory, Musk is on the decline and Zuckerberg is on the rise. Musk's net worth is down $83.9 billion year-to-date in 2025, while Zuckerberg's wealth is up $46.9 billion. This comes, of course, with Tesla stock down 22% in 2025 and Meta stock up 22% in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/07/46329375/x-ceo-yaccarino-splits-with-elon-musk-after-two-years-says-best-is-yet-to-come-for-social-platform">X CEO Yaccarino Splits With Elon Musk After Two Years, Says &#8216;Best Is Yet To Come&#8217; For Social Platform</a></li>
</ul>

Social Media

General

Musk Vs Zuckerberg: Two Richest Men Battle Over Daily Social Media Users

Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) has outperformed the market over the past 20 years by 5.17% on an annualized basis producing an average annual return of 13.66%. Currently, Adobe has a market capitalization of $158.46 billion. 
Buying $100 In ADBE: If an investor had bought $100 of ADBE stock 20 years ago, it would be worth $1,291.97 today based on a price of $373.54 for ADBE at the time of writing.
<h3>Adobe's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752101114_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADBE

Here's How Much $100 Invested In Adobe 20 Years Ago Would Be Worth Today

Longevity startup Circulate Health<a href="https://www.prnewswire.com/news-releases/circulate-health-raises-12-million-in-seed-funding-to-accelerate-research-in-longevity-and-expand-therapeutic-plasma-exchange-tpe-treatment-centers-302492382.html"> announced</a> Wednesday that it has raised $12 million in seed funding to expand a pricey outpatient service it calls ‘targeted blood cleaning.'
The treatment, known as therapeutic plasma exchange, removes a patient's blood, separates the liquid plasma, and then returns the blood cells with a replacement fluid. Circulate Health says this process clears out inflammation and biological compounds linked to aging.
According to<a href="https://www.geekwire.com/2025/seattle-startup-circulate-health-raises-12m-for-pricey-blood-cleaning-longevity-service/"> GeekWire</a>, the procedure costs between $8,000 and $10,000 per session and is not covered by insurance. Since May 2024, the Seattle-based company says it has completed over 1,000 treatments in eight states through a network of 24 clinics.
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
<h2 class="wp-block-heading">A Study Shows Youthful Results But Critics Remain Skeptical</h2>
Circulate Health co-founder and CEO Dr. Brad Younggren told GeekWire that they "saw a lot of expected outcomes that would be consistent with cellular rejuvenation."
A<a href="https://onlinelibrary.wiley.com/doi/10.1111/acel.70103"> study</a> published in Aging Cell by Circulate Health and Buck Institute for Research on Aging observed 42 participants, with one group receiving six plasma exchanges plus a dose of antibodies. That group experienced a 2.61-year average reduction in biological age, according to the company. However, the trial lasted only three to five months, and experts say more research is needed.
Dr. Jeffrey Winters, chair of transfusion medicine at the Mayo Clinic, told the<a href="https://www.nytimes.com/2025/05/28/well/plasma-exchange-longevity.html"> New York Times</a> that the findings do not show the therapy leads to longer or healthier lives. The study's final blood samples showed diminishing effects, suggesting that any benefit may taper off over time.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
<h2 class="wp-block-heading">Backed By Khosla Ventures, Built on Research From the Buck Institute</h2>
Circulate Health operated in stealth for two years and officially launched in January 2024 when Younggren joined as CEO. According to GeekWire, his co-founder is Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging.
<a href="https://www.benzinga.com/news/25/04/45027859/khosla-ventures-leads-16-2m-series-a-in-loti-ai-backed-by-wme-caa-to-shield-celebrities-from-deepfake-threats">Khosla Ventures</a> led the $12 million seed round, joined by Seaside Ventures and CSC Ventures. Robbie Schwietzer, former chief product officer at 98point6, also joined the Circulate Health team as chief operating officer, GeekWire says.
&#8220;We incubated Circulate to explore whether a safe, well-understood therapy like therapeutic plasma exchange could counter the deleterious effects of aging, and offer broader health benefits like potentially removing microplastics from the body,&#8221; Khosla Ventures partner Alex Morgan said in the statement. &#8220;Early clinical results are promising, and we&#8217;re excited to continue backing the team as they work to make therapeutic plasma exchange more accessible to more people.&#8221;
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<h2 class="wp-block-heading">Longevity Tech is Booming as Wealthy Clients Chase Youth</h2>
The U.S. longevity tech market has pulled in $1.8 billion in investment since 2021, according to<a href="https://pitchbook.com/news/reports/2025-emerging-space-brief-longevity-tech"> PitchBook</a>. In 2024 alone, startups in the space raised nearly $300 million as investors doubled down on areas like epigenetic reprogramming and senolytics, fields targeting the root causes of aging rather than just its symptoms.
Backed by visionaries such as <a href="https://www.benzinga.com/news/topics/25/06/45961532/nvidia-and-samsung-back-4-5b-robotics-startup-skild-ai-with-35m-as-softbank-and-jeff-bezos-drive-push-into-consumer-robots">Jeff Bezos</a> and Sam Altman, PitchBook says the sector is gaining momentum despite regulatory uncertainty and long development timelines.
Circulate Health's competitors include MaxWell Clinic and Next Health, both offering similar treatments. The difference, Circulate Health claims, according to Geekwire, lies in their replacement fluid: albumin instead of saline, and the addition of targeted antibodies. Younggren said their method aims to improve longevity outcomes beyond what traditional plasma donation protocols offer.
While the treatment remains expensive and uncovered by insurance, Younggren believes it could help prevent costly chronic illness down the line. "This notion of making America healthy again fits right in with what we're trying to do," Younggren told GeekWire.
Read Next: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
Image: Shutterstock

Personal Finance

Seattle Startup Backed By Khosla Ventures Charges $10,000 For 'Blood Cleaning' That Claims To Make You Biologically 2.61 Years Younger

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) has outperformed the market over the past 15 years by 3.5% on an annualized basis producing an average annual return of 15.79%. Currently, Tenet Healthcare has a market capitalization of $15.92 billion. 
Buying $1000 In THC: If an investor had bought $1000 of THC stock 15 years ago, it would be worth $9,355.90 today based on a price of $171.40 for THC at the time of writing.
<h3>Tenet Healthcare's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752100211_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Tenet Healthcare 15 Years Ago Would Be Worth Today

Shell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) has outperformed the market over the past 5 years by 2.07% on an annualized basis producing an average annual return of 16.44%. Currently, Shell has a market capitalization of $210.28 billion. 
Buying $100 In SHEL: If an investor had bought $100 of SHEL stock 5 years ago, it would be worth $221.32 today based on a price of $71.61 for SHEL at the time of writing.
<h3>Shell's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752099319_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SHEL

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Across the recent three months, 21 analysts have shared their insights on FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $280.1, along with a high estimate of $330.00 and a low estimate of $220.00. A 3.97% drop is evident in the current average compared to the previous average price target of $291.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1752098468_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of FedEx among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ariel Rosa</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$278.00</td>
<td>$259.00</td>
</tr>
<tr>
<td>Lucas Servera</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$275.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Ken Hoexter</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$245.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Patrick Tyler Brown</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Ariel Rosa</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$259.00</td>
<td>$267.00</td>
</tr>
<tr>
<td>Brian Ossenbeck</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jason Seidl</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$269.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>J. Bruce Chan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$315.00</td>
<td>$329.00</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$295.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$297.00</td>
<td>$311.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$320.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Christian Wetherbee</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$235.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>J. Bruce Chan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$329.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>David Vernon</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$249.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$311.00</td>
<td>$331.00</td>
</tr>
<tr>
<td>Daniel Imbro</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Fadi Chamoun</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$260.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Ken Hoexter</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$270.00</td>
<td>$272.00</td>
</tr>
<tr>
<td>Lucas Servera</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Christian Wetherbee</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to FedEx. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of FedEx compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of FedEx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of FedEx's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on FedEx analyst ratings.</a>
<h2>Get to Know FedEx Better</h2>
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In fiscal 2025, the firm's Federal Express segment—which houses the core package delivery operations—made up 86% of total revenue, with 10% coming from FedEx Freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.
<h3>Financial Milestones: FedEx's Journey</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: FedEx displayed positive results in 3M. As of 31 May, 2025, the company achieved a solid revenue growth rate of approximately 0.27%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: FedEx's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.42% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): FedEx's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.02%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.91%, the company showcases effective utilization of assets.
Debt Management: FedEx's debt-to-equity ratio is below the industry average at 1.33, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing FedEx: Insights From 21 Financial Analysts

Analysts' ratings for Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $29.44, a high estimate of $35.00, and a low estimate of $22.00. Highlighting a 17.07% decrease, the current average has fallen from the previous average price target of $35.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1752098459_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Dow among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$22.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Frank Mitsch</td>
<td>Fermium Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$34.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Frank Mitsch</td>
<td>Fermium Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$28.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dow. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Dow compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Dow's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Dow's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DOW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dow analyst ratings.</a>
<h2>Unveiling the Story Behind Dow</h2>
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.
<h3>Unraveling the Financial Story of Dow</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Dow's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -3.1%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.
Net Margin: Dow's net margin excels beyond industry benchmarks, reaching -2.97%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Dow's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.82% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Dow's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.54%, the company showcases efficient use of assets and strong financial health.
Debt Management: Dow's debt-to-equity ratio is below the industry average. With a ratio of 1.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 9 Analyst Projections For Dow

Gates Industrial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTES#NYSE">GTES</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $23.38, with a high estimate of $26.00 and a low estimate of $21.00. This upward trend is evident, with the current average reflecting a 2.77% increase from the previous average price target of $22.75.
<img src="https://www.benzinga.com/files/images/story/2025/1752098451_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Gates Industrial Corp among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Chris Snyder</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Gates Industrial Corp. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Gates Industrial Corp compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Gates Industrial Corp's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Gates Industrial Corp's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GTES/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gates Industrial Corp analyst ratings.</a>
<h2>About Gates Industrial Corp</h2>
Gates Industrial Corp PLC is a manufacturer of engineered power transmission and fluid power solutions. The company has two operating segments; Power Transmission and Fluid Power segments. The Power Transmission solutions convey power and control motion. It is used in applications in which belts, chains, cables, geared transmissions, or direct drives transfer power from an engine or motor to another part or system. The Fluid power solutions are used in applications in which hoses and rigid tubing assemblies either transfer power hydraulically or convey fluids, gases, or granular materials from one location to another. The company generates key revenue from the Power Transmission segment. Company operates in USA, United Kingdom, Luxembourg, EMEA, with majority revenue from USA.
<h3>Understanding the Numbers: Gates Industrial Corp's Finances</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Decline in Revenue: Over the 3M period, Gates Industrial Corp faced challenges, resulting in a decline of approximately -1.74% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Gates Industrial Corp's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 7.31%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.02%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Gates Industrial Corp's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.91%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.8, Gates Industrial Corp faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GTES

Forecasting The Future: 8 Analyst Projections For Gates Industrial Corp

During the last three months, 7 analysts shared their evaluations of Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $4.57, a high estimate of $6.00, and a low estimate of $3.00. Observing a 13.12% increase, the current average has risen from the previous average price target of $4.04. 
<img src="https://www.benzinga.com/files/images/story/2025/1752098442_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Agilon Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$3.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$3.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$5.00</td>
<td>$3.25</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$6.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Agilon Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Agilon Health compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Agilon Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Agilon Health's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AGL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Agilon Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Agilon Health</h2>
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
<h3>Financial Milestones: Agilon Health's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3M period, Agilon Health faced challenges, resulting in a decline of approximately -4.46% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Agilon Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.79% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Agilon Health's ROE excels beyond industry benchmarks, reaching 2.49%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.66%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Agilon Health's debt-to-equity ratio is below the industry average at 0.08, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Agilon Health Stands With Analysts

In the preceding three months, 7 analysts have released ratings for FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $46.86, with a high estimate of $53.00 and a low estimate of $41.00. This current average has increased by 5.47% from the previous average price target of $44.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1752098432_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of FMC among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$51.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to FMC. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of FMC compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of FMC's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of FMC's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FMC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on FMC analyst ratings.</a>
<h2>All You Need to Know About FMC</h2>
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
<h3>Breaking Down FMC's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3M period, FMC faced challenges, resulting in a decline of approximately -13.79% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.96%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): FMC's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.35%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): FMC's ROA excels beyond industry benchmarks, reaching -0.13%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.91, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About FMC Stock

In the current market session, Texas Pacific Land Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>) share price is at $1047.55, after a 0.10% spike. Moreover, over the past month, the stock fell by 4.77%, but in the past year, went up by 33.43%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1752098418_0.png" alt="Past Year Chart" />

<h3>A Look at Texas Pacific Land P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 18.17 in the Oil, Gas &amp; Consumable Fuels industry, Texas Pacific Land Inc. has a higher P/E ratio of 52.35. Shareholders might be inclined to think that Texas Pacific Land Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1752098418_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Texas Pacific Land Inc's Price Over Earnings

Analysts' ratings for Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) over the last quarter vary from bullish to bearish, as provided by 13 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $103.54, a high estimate of $130.00, and a low estimate of $85.00. Witnessing a positive shift, the current average has risen by 12.08% from the previous average price target of $92.38.
<img src="https://www.benzinga.com/files/images/story/2025/1752098418_0_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Johnson Controls Intl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$116.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Amit Mehrotra</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$116.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Nicole Deblase</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Chris Snyder</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$98.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson Controls Intl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Johnson Controls Intl compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Johnson Controls Intl's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Johnson Controls Intl's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/JCI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Johnson Controls Intl analyst ratings.</a>
<h2>Get to Know Johnson Controls Intl Better</h2>
Johnson Controls manufactures, installs, and services commercial HVAC systems, building management platforms and controls, fire and security solutions, and industrial refrigeration units. Commercial HVAC and fire and security each account for approximately 45% of sales, while industrial refrigeration and other solutions account for the remaining 10% of revenue. In fiscal 2024, Johnson Controls generated nearly $23 billion in pro forma revenue.
<h3>Johnson Controls Intl: Delving into Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Johnson Controls Intl's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 1.41%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Johnson Controls Intl's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 8.42%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 3.02%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Johnson Controls Intl's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.13%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Johnson Controls Intl's debt-to-equity ratio is below the industry average at 0.63, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

13 Analysts Assess Johnson Controls Intl: What You Need To Know

Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) has outperformed the market over the past 10 years by 1.91% on an annualized basis producing an average annual return of 13.38%. Currently, Franco-Nevada has a market capitalization of $30.66 billion. 
Buying $100 In FNV: If an investor had bought $100 of FNV stock 10 years ago, it would be worth $349.63 today based on a price of $159.20 for FNV at the time of writing.
<h3>Franco-Nevada's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752098414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Luminar Technologies, Inc. - LAZR

Penny Stocks

LAZR Investors Have Opportunity to Join Luminar Technologies, Inc. Fraud Investigation with the Schall Law Firm

Legal

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Luminar Technologies, Inc. (NASDAQ: LAZR) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Comments

Luminar Technologies

Noticias

Últimas noticias sobre Luminar Technologies (NASDAQ:LAZR) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL